Comparison of next-generation sequencing and mutation-specific platforms in clinical practice

Area of Science:

• Molecular diagnostics
• Oncology
• Genomic technologies

Background:

• Lung cancer diagnosis relies on accurate mutation detection.
• Traditional genotyping platforms and next-generation sequencing (NGS) are used for this purpose.
• Evaluating platform performance in a clinical setting is crucial.

Purpose of the Study:

• To compare next-generation sequencing (NGS) platforms with mutation-specific analysis platforms.
• The comparison focuses on sensitivity, specificity, cost, capacity, and ease of use in a clinical context.
• This evaluation aims to guide platform selection for lung cancer mutation analysis.

Main Methods:

• Analysis of 25 formalin-fixed, paraffin-embedded lung cancer samples.
• Testing for known KRAS and EGFR hotspot mutations using two dedicated genotyping platforms (cobas, Rotor-Gene) and two NGS platforms (454 GS junior, Ion Torrent PGM).
• Comparison based on sensitivity, specificity, cost, capacity, and ease of use.

Main Results:

• All platforms, except the 454 GS junior, detected known mutations and an additional KRAS mutation.
• Dedicated genotyping platforms were faster and easier to use than NGS platforms.
• NGS platforms offered high capacity, delivering all mutation data simultaneously.

Conclusions:

• Mutation detection sensitivity was comparable across all tested platforms.
• The choice between dedicated genotyping and NGS platforms involves a trade-off between speed and the breadth of genetic information obtained.
• Clinical application requires balancing rapid results with comprehensive genomic data.